imiquimod has been researched along with sphingosine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bäumer, W; Dickhaut, J; Japtok, L; Kietzmann, M; Kleuser, B; Mischke, R; Schaper, K | 1 |
| Cho, KA; Hahn, S; Kim, YH; Lee, Y; Park, JW; Park, WJ; Ryu, KH; Shin, SH; Woo, SY | 1 |
2 other study(ies) available for imiquimod and sphingosine
| Article | Year |
|---|---|
Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cell Differentiation; Cell Proliferation; Dermatologic Agents; Disease Models, Animal; Female; Fingolimod Hydrochloride; Humans; Imiquimod; Keratinocytes; Local Lymph Node Assay; Lysophospholipids; Mice; Mice, Inbred BALB C; Mice, SCID; Propylene Glycols; Psoriasis; Receptors, Lysosphingolipid; Skin; Skin Transplantation; Sphingosine; Sphingosine-1-Phosphate Receptors; Time Factors | 2013 |
Inhibiting Sphingosine Kinase 2 Derived-sphingosine-1-phosphate Ameliorates Psoriasis-like Skin Disease via Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes in Mice.
Topics: Administration, Topical; Animals; CD4-Positive T-Lymphocytes; Cell Differentiation; Ceramidases; Disease Models, Animal; Enzyme Inhibitors; Gene Expression; Imiquimod; Immunity; Inflammation; Interleukin-17; Lysophospholipids; Male; Mice; Phosphotransferases (Alcohol Group Acceptor); Psoriasis; Quinolones; RNA, Messenger; Sphingosine; Suppressor of Cytokine Signaling 1 Protein; Th17 Cells | 2019 |